Growing prevalence of blood disorders has led to an upsurge in demand
for the rare hematology globally. However, limited resources and
disease-specific information available for development of improved
treatment techniques is likely to impact growth of the global rare
hematology market adversely. Transparency Market Research states that
the global market of rare hematology is projected to reflect a CAGR
of 6.2% over the forecast period.
Request for Sample Copy of Report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=34736
Growth of the global rare hematology market is mainly bound with
various macro-economic and micro-economic factors. Prevalence of
blood related disorders such as leukemia, anemia, sickle cell anemia
and myeloma continues to contribute towards the global market growth
of rare hematology. Growing demand for conducting diagnosis process
in comparatively short time has led the hematologists to concentrate
on developing enhanced techniques of diagnosis. Moreover, the
hematologists are mainly concentrating on the early diagnosis phase
of blood disorder to develop techniques that successfully treat the
patients. Attributed to such factors, the global market of rare
hematology is projected to witness significant growth over the
forecast period.
In order to improve and develop the diagnosis treatment procedures,
the hematologists are focusing on leading extensive research related
to the molecular biology and genetics. With a well understand various
hematology disorders, the hematologist can develop improved and
shorter the treatment techniques. Through the research conducted, the
hematologist can conveniently identify the therapeutic targets, which
helps in catering to the blood diseases to the molecular level. On
the basis of the extensive research conducted, the hematologist are
focusing on developing new techniques of treatment conducting in
short time. Moreover, hundreds of clinical trials that are at the
final phase have not received certification by the FDA and are yet to
be approved and evaluated. American Society of Hematology, Myeloma
Foundation and International National Hemophilia Foundation are
various advocacy groups that also continues to provide support and
resources for the clinicians, caregivers and patients.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=34736
Limited support for extensive research from the foundations that are
focusing on specific diseases is expected to restraint the global
market growth of rare hematology. The Kakkis EverLife Foundations
states that various rare hematology drugs that were finalized for
treatment have not received authorization by the FDA. Growing demand
for the FDA approved drugs has led to growing investment in research
and development for enhanced treatment process. In addition, various
economic, social and political situations in the developing countries
witness improper supervision of their treatment conditions.
Moreover, caregivers, researchers, patients and advocacy groups are
incorporating to spread awareness related to blood diseases.
Increasing awareness among the patient population is likely to
benefit the drug developers as it enables the patient groups to
register for clinical trials. In addition, extensive research on rare
hematology diseases are increasingly gaining momentum in the
developed countries including U.S. In 2016, the U.S. House of
Representatives passed the 21st Century Cures Act that was mainly
concentrating on integrating opinions of various patients, which
could contribute towards progress of the clinical trials for these
diseases. These factors are further expected to impact the global
market growth of rare hematology positively.
With the growing need to treat blood related disorders has led the
hematologists to opt for recombinant factor treatments. Based on
treatment type, the recombinant factors segment is projected to
witness the highest revenue growth, representing more than US$ 4,000
Mn by 2022-end. However, the plasma derived factors treatment type
segment is projected to witness the fastest growth in the global
market of rare hematology during the forecast period. By age, the
adult segment is projected to witness a robust revenue growth,
recording more than US$ 3,000 Mn by 2017-end. On the other hand, the
pediatric age segment is projected to reflect a healthy CAGR through
2022.
Report Overview @
https://www.transparencymarketresearch.com/rare-hematology-market.html
Major players in the global market of rare hematology are Biogen
Inc., Shire plc, Bayer Healthcare AG, Novo Nordisk A/S, Pfizer Inc.,
CSL Behring LLC, Celgene Corporation, PRA Health Sciences, Amgen Inc.
and Alexion Pharmaceuticals, Inc.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment